643:
620:
42:
51:
1802:
1387:
1343:
1299:
837:
Cinacalcet was approved in the United States in March 2004, and in the
European Union in October 2004. It was the first allosteric G protein-coupled receptor modulator to enter the pharmaceutical market. In 2013, cinacalcet was the 76th most prescribed medicine in the United States.
1284:
868:
the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care
1051:
is the principal negative regulator of parathyroid hormone secretion. Cinacalcet increases the sensitivity of calcium receptors on parathyroid cells to reduce parathyroid hormone (PTH) levels and thus decrease serum calcium levels.
884:
primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is
910:(decreased calcium levels) is a contraindication to the use of cinacalcet. Those who have serum calcium levels less than 7.5 mg/dL should not be started on cinacalcet. Hypocalcemia symptoms include
926:. Cinacalcet should not be administered until serum calcium levels are above 8.0 mg/dL and/or hypocalcemia symptoms are resolved. Cinacalcet is not approved for pediatric use in the United States.
220:
1272:
1552:
175:
1372:
767:
854:
in people with parathyroid carcinoma. Cinacalcet can also be used to treat severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo
709:
1616:
73:
723:
896:
Cinacalcet has pregnancy category C in the US, meaning that adequate and well-controlled studies involving cinacalcet in pregnant women have not been done.
1328:
1832:
1404:
Bräuner-Osborne H, Wellendorph P, Jensen AA (2007). "Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors".
751:
InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
1257:
Text was copied from this source which is copyright
European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1670:
1508:
1022:. Dose adjustments may be necessary if people are treated with CYP3A4 and CYP1A2 inhibitors and medications that are metabolized by CYP2D6.
1562:
1837:
1360:
1108:
1609:
743:
865:
the treatment of secondary hyperparathyroidism (HPT) in adults with end stage renal disease (ESRD) on maintenance dialysis therapy.
1273:"FDA Drug Safety Communication: Pediatric clinical studies of Sensipar (cinacalcet hydrochloride) suspended after report of death"
937:
Clinical trials conducted in the United States by Amgen to determine whether the drug is safe in children were halted by the U.S.
1186:
1143:
357:
205:
105:
1827:
1842:
934:
Common side effects of cinacalcet include upset stomach, vomiting, diarrhea, dizziness, nausea, weakness, and chest pain.
899:
Studies have not been done in lactating women; therefore, it is not known whether cinacalcet is excreted into human milk.
847:
1602:
1366:
1322:
1278:
1047:
that is expressed in various human organ tissues. The calcium-sensing receptors on the surface of the chief cell of the
938:
796:
512:
792:
599:
124:
1822:
1792:
1242:
1660:
1044:
820:
1316:
461:
161:
638:
1557:
588:
288:
1847:
1040:
800:
452:
323:
441:
1655:
1641:
872:
part of a therapeutic regimen including phosphate binders and/or vitamin D sterols, as appropriate.
615:
384:
168:
41:
1529:
808:
135:
1500:
1494:
1504:
1421:
1048:
855:
568:
246:
233:
63:
1413:
1237:
812:
655:
501:
393:
268:
521:
50:
1806:
1755:
1745:
1100:
298:
276:
642:
619:
1760:
1816:
1765:
1719:
1650:
1391:
1347:
1303:
1135:
851:
631:
97:
1775:
1665:
1632:
1036:
956:
907:
804:
418:
188:
183:
1074:
83:
875:
the treatment of parathyroid carcinoma and primary hyperparathyroidism in adults.
1735:
1628:
911:
91:
1499:(13th ed.). Burlington, MA: Jones & Bartlett Learning. 2014. pp.
1417:
1136:"Mimpara 30 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)"
1740:
1693:
923:
816:
685:
492:
1770:
1698:
1594:
336:
77:
1439:
1425:
33:
1524:
1522:
1520:
949:
Serious side effects, including overdose symptoms, of cinacalcet include:
941:(FDA) in February 2013, following the death of a 14-year-old participant.
1191:
999:
831:
472:
119:
481:
17:
1625:
1584:
1465:
970:
915:
404:
1019:
1015:
1011:
994:
980:
966:
919:
827:
579:
341:
315:
311:
307:
846:
In the United States, cinacalcet is indicated for the treatment of
548:
541:
986:
708:
699:
559:
303:
1390:
This article incorporates text from this source, which is in the
1346:
This article incorporates text from this source, which is in the
1302:
This article incorporates text from this source, which is in the
990:
974:
962:
532:
252:
227:
1598:
240:
114:
1553:"Amgen Pediatric Trials of Sensipar Halted by FDA After Death"
1317:"Drug Approval Package: Sensipar (Cinacalcet HCI) NDA #021688"
604:
214:
146:
774:
850:
in people with chronic kidney disease on dialysis and
1790:
1489:
1487:
1181:
1069:
1067:
1065:
1039:(i.e. it mimics the action of calcium on tissues) by
1010:
Cinacalcet is a strong inhibitor of the liver enzyme
1179:
1177:
1175:
1173:
1171:
1169:
1167:
1165:
1163:
1161:
1728:
1707:
1686:
1679:
1640:
1187:"Sensipar- cinacalcet hydrochloride tablet, coated"
861:In the European Union cinacalcet is indicated for:
697:
684:
654:
649:
630:
598:
578:
558:
531:
511:
491:
471:
460:
451:
428:
403:
383:
348:
335:
322:
297:
287:
275:
267:
204:
199:
174:
160:
134:
104:
90:
72:
62:
57:
823:that is expressed in various human organ tissues.
878:the reduction of hypercalcaemia in adults with:
731:CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F
440:
417:
1267:
1265:
1263:
1232:
1230:
392:
1228:
1226:
1224:
1222:
1220:
1218:
1216:
1214:
1212:
1210:
1130:
1128:
1126:
1610:
1466:"Sales Statistics for Sensipar Prescriptions"
8:
1075:"Cinacalcet (Sensipar) Use During Pregnancy"
791:among others, is a medication used to treat
123:
32:
260:In general: ℞ (Prescription only)
1683:
1617:
1603:
1595:
641:
618:
500:
49:
40:
520:
1797:
1061:
748:
728:
614:
480:
362:
96:
632:
31:
1671:Recombinant human parathyroid hormone
1287:from the original on 24 December 2019
1140:electronic medicines compendium (emc)
826:The most common side effects include
587:
567:
82:
7:
1375:from the original on 7 December 2019
1331:from the original on 7 December 2019
1146:from the original on 7 December 2019
1111:from the original on 7 December 2019
1035:Cinacalcet is a drug that acts as a
431:
187:
1532:. U.S. National Library of Medicine
547:
540:
408:
25:
1800:
1440:"U.S. Pharmaceutical Statistics"
1385:
1341:
1297:
1014:and is partially metabolized by
985:sudden tightening of muscles in
678:
672:
666:
1680:Anti-parathyroid hormone agents
807:(i.e., it mimics the action of
756:Key:VDHAWDNDOKGFTD-MRXNPFEDSA-N
1833:Systemic hormonal preparations
660:
1:
848:secondary hyperparathyroidism
1551:Edney A (26 February 2013).
1367:Food and Drug Administration
1323:Food and Drug Administration
1279:Food and Drug Administration
939:Food and Drug Administration
797:tertiary hyperparathyroidism
787:, sold under the brand name
283:increases if taken with food
793:primary hyperparathyroidism
1864:
1418:10.2174/138945007779315614
650:Chemical and physical data
1838:Trifluoromethyl compounds
1661:Parathyroid gland extract
1496:2014 Nurses Drug Handbook
1243:European Medicines Agency
764:
739:
719:
353:
48:
39:
1045:calcium-sensing receptor
961:unusual feelings of the
821:calcium-sensing receptor
892:Pregnancy and lactation
803:. Cinacalcet acts as a
1687:Calcitonin derivatives
1558:Bloomberg Businessweek
881:parathyroid carcinoma;
1828:Nephrology procedures
1041:allosteric activation
801:parathyroid carcinoma
344:(80%) and fecal (15%)
1843:1-Naphthyl compounds
1406:Current Drug Targets
1656:Palopegteriparatide
1642:Parathyroid hormone
1327:. 7 December 2019.
1283:. 15 January 2016.
1031:Mechanism of action
918:, muscle cramping,
236:(Prescription only)
223:(Prescription only)
36:
1472:. 2 September 2020
1101:"Sensipar Tablets"
819:activation of the
1823:CYP2D6 inhibitors
1788:
1787:
1784:
1783:
1510:978-1-284-03115-7
1195:. 5 December 2019
1049:parathyroid gland
903:Contraindications
856:parathyroidectomy
782:
781:
710:Interactive image
600:CompTox Dashboard
256:
244:
231:
218:
150:
117:
68:Sensipar, Mimpara
27:Chemical compound
16:(Redirected from
1855:
1805:
1804:
1803:
1796:
1684:
1619:
1612:
1605:
1596:
1589:
1588:
1581:
1575:
1574:
1572:
1570:
1561:. Archived from
1548:
1542:
1541:
1539:
1537:
1526:
1515:
1514:
1491:
1482:
1481:
1479:
1477:
1462:
1456:
1455:
1453:
1451:
1436:
1430:
1429:
1401:
1395:
1389:
1388:
1384:
1382:
1380:
1357:
1351:
1345:
1344:
1340:
1338:
1336:
1313:
1307:
1301:
1300:
1296:
1294:
1292:
1269:
1258:
1256:
1254:
1252:
1247:. 22 August 2019
1234:
1205:
1204:
1202:
1200:
1183:
1156:
1155:
1153:
1151:
1132:
1121:
1120:
1118:
1116:
1105:NPS MedicineWise
1097:
1091:
1090:
1088:
1086:
1071:
979:muscle aches or
885:contraindicated.
778:
777:
770:
712:
692:
680:
674:
668:
662:
645:
634:
623:
622:
608:
606:
591:
571:
551:
544:
524:
504:
484:
464:
444:
434:
433:
421:
411:
410:
396:
327:
254:
251:
242:
239:
229:
226:
216:
213:
191:
148:
145:
127:
116:
113:
100:
86:
53:
44:
37:
35:
21:
1863:
1862:
1858:
1857:
1856:
1854:
1853:
1852:
1813:
1812:
1811:
1801:
1799:
1791:
1789:
1780:
1756:Doxercalciferol
1746:Cholecalciferol
1724:
1703:
1675:
1636:
1623:
1593:
1592:
1583:
1582:
1578:
1568:
1566:
1565:on 2 March 2013
1550:
1549:
1545:
1535:
1533:
1528:
1527:
1518:
1511:
1493:
1492:
1485:
1475:
1473:
1464:
1463:
1459:
1449:
1447:
1446:. February 2014
1438:
1437:
1433:
1403:
1402:
1398:
1386:
1378:
1376:
1359:
1358:
1354:
1342:
1334:
1332:
1315:
1314:
1310:
1298:
1290:
1288:
1271:
1270:
1261:
1250:
1248:
1236:
1235:
1208:
1198:
1196:
1185:
1184:
1159:
1149:
1147:
1142:. 8 July 2019.
1134:
1133:
1124:
1114:
1112:
1099:
1098:
1094:
1084:
1082:
1073:
1072:
1063:
1058:
1033:
1028:
1008:
947:
932:
930:Adverse effects
905:
894:
844:
773:
771:
768:(what is this?)
765:
760:
757:
752:
747:
746:
735:
732:
727:
726:
715:
690:
677:
671:
665:
626:
602:
594:
574:
554:
527:
507:
487:
467:
447:
430:
424:
407:
399:
379:
376:
374:
361:
360:
325:
289:Protein binding
282:
277:Bioavailability
269:Pharmacokinetic
263:
195:
163:
156:
137:
130:
28:
23:
22:
15:
12:
11:
5:
1861:
1859:
1851:
1850:
1845:
1840:
1835:
1830:
1825:
1815:
1814:
1810:
1809:
1786:
1785:
1782:
1781:
1779:
1778:
1773:
1768:
1763:
1761:Ergocalciferol
1758:
1753:
1748:
1743:
1738:
1732:
1730:
1726:
1725:
1723:
1722:
1717:
1711:
1709:
1705:
1704:
1702:
1701:
1696:
1690:
1688:
1681:
1677:
1676:
1674:
1673:
1668:
1663:
1658:
1653:
1647:
1645:
1638:
1637:
1624:
1622:
1621:
1614:
1607:
1599:
1591:
1590:
1576:
1543:
1516:
1509:
1483:
1457:
1431:
1396:
1352:
1308:
1259:
1238:"Mimpara EPAR"
1206:
1157:
1122:
1107:. 1 May 2018.
1092:
1081:. 19 July 2019
1060:
1059:
1057:
1054:
1032:
1029:
1027:
1024:
1007:
1004:
1003:
1002:
997:
983:
977:
959:
954:
946:
943:
931:
928:
904:
901:
893:
890:
889:
888:
887:
886:
882:
876:
873:
870:
866:
843:
840:
780:
779:
762:
761:
759:
758:
755:
753:
750:
742:
741:
740:
737:
736:
734:
733:
730:
722:
721:
720:
717:
716:
714:
713:
705:
703:
695:
694:
688:
682:
681:
675:
669:
663:
658:
652:
651:
647:
646:
636:
628:
627:
625:
624:
611:
609:
596:
595:
593:
592:
584:
582:
576:
575:
573:
572:
564:
562:
556:
555:
553:
552:
545:
537:
535:
529:
528:
526:
525:
517:
515:
509:
508:
506:
505:
497:
495:
489:
488:
486:
485:
477:
475:
469:
468:
466:
465:
457:
455:
449:
448:
446:
445:
437:
435:
426:
425:
423:
422:
414:
412:
401:
400:
398:
397:
389:
387:
381:
380:
378:
377:
375:propan-1-amine
364:
356:
355:
354:
351:
350:
346:
345:
339:
333:
332:
331:30 to 40 hours
329:
320:
319:
301:
295:
294:
291:
285:
284:
279:
273:
272:
265:
264:
262:
261:
258:
249:
237:
224:
210:
208:
202:
201:
197:
196:
194:
193:
180:
178:
172:
171:
166:
164:administration
158:
157:
155:
154:
152:
142:
140:
132:
131:
129:
128:
110:
108:
102:
101:
94:
88:
87:
80:
70:
69:
66:
60:
59:
55:
54:
46:
45:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1860:
1849:
1846:
1844:
1841:
1839:
1836:
1834:
1831:
1829:
1826:
1824:
1821:
1820:
1818:
1808:
1798:
1794:
1777:
1774:
1772:
1769:
1767:
1766:Etelcalcetide
1764:
1762:
1759:
1757:
1754:
1752:
1749:
1747:
1744:
1742:
1739:
1737:
1734:
1733:
1731:
1727:
1721:
1720:Etelcalcetide
1718:
1716:
1713:
1712:
1710:
1708:Calcimimetics
1706:
1700:
1697:
1695:
1692:
1691:
1689:
1685:
1682:
1678:
1672:
1669:
1667:
1664:
1662:
1659:
1657:
1654:
1652:
1651:Abaloparatide
1649:
1648:
1646:
1644:and analogues
1643:
1639:
1634:
1630:
1627:
1620:
1615:
1613:
1608:
1606:
1601:
1600:
1597:
1586:
1580:
1577:
1564:
1560:
1559:
1554:
1547:
1544:
1531:
1525:
1523:
1521:
1517:
1512:
1506:
1502:
1498:
1497:
1490:
1488:
1484:
1471:
1467:
1461:
1458:
1445:
1441:
1435:
1432:
1427:
1423:
1419:
1415:
1412:(1): 169–84.
1411:
1407:
1400:
1397:
1393:
1392:public domain
1374:
1370:
1368:
1362:
1356:
1353:
1349:
1348:public domain
1330:
1326:
1324:
1318:
1312:
1309:
1305:
1304:public domain
1286:
1282:
1280:
1274:
1268:
1266:
1264:
1260:
1246:
1244:
1239:
1233:
1231:
1229:
1227:
1225:
1223:
1221:
1219:
1217:
1215:
1213:
1211:
1207:
1194:
1193:
1188:
1182:
1180:
1178:
1176:
1174:
1172:
1170:
1168:
1166:
1164:
1162:
1158:
1145:
1141:
1137:
1131:
1129:
1127:
1123:
1110:
1106:
1102:
1096:
1093:
1080:
1076:
1070:
1068:
1066:
1062:
1055:
1053:
1050:
1046:
1042:
1038:
1030:
1025:
1023:
1021:
1017:
1013:
1005:
1001:
998:
996:
992:
988:
984:
982:
978:
976:
972:
968:
964:
960:
958:
955:
952:
951:
950:
944:
942:
940:
935:
929:
927:
925:
921:
917:
913:
909:
902:
900:
897:
891:
883:
880:
879:
877:
874:
871:
867:
864:
863:
862:
859:
857:
853:
852:hypercalcemia
849:
841:
839:
835:
833:
829:
824:
822:
818:
814:
810:
806:
802:
798:
794:
790:
786:
776:
769:
763:
754:
749:
745:
738:
729:
725:
718:
711:
707:
706:
704:
701:
696:
689:
687:
683:
659:
657:
653:
648:
644:
640:
637:
635:
633:ECHA InfoCard
629:
621:
617:
616:DTXSID8048286
613:
612:
610:
601:
597:
590:
589:ChEMBL1201284
586:
585:
583:
581:
577:
570:
566:
565:
563:
561:
557:
550:
546:
543:
539:
538:
536:
534:
530:
523:
519:
518:
516:
514:
510:
503:
499:
498:
496:
494:
490:
483:
479:
478:
476:
474:
470:
463:
459:
458:
456:
454:
450:
443:
439:
438:
436:
429:PubChem
427:
420:
416:
415:
413:
406:
402:
395:
391:
390:
388:
386:
382:
372:
368:
363:
359:
352:
347:
343:
340:
338:
334:
330:
328:
321:
317:
313:
309:
305:
302:
300:
296:
292:
290:
286:
280:
278:
274:
270:
266:
259:
257: Rx-only
250:
248:
238:
235:
225:
222:
212:
211:
209:
207:
203:
198:
190:
185:
182:
181:
179:
177:
173:
170:
167:
165:
159:
153:
144:
143:
141:
139:
133:
126:
121:
112:
111:
109:
107:
103:
99:
95:
93:
89:
85:
81:
79:
75:
71:
67:
65:
61:
58:Clinical data
56:
52:
47:
43:
38:
30:
19:
1848:Pharmacology
1776:Paricalcitol
1750:
1714:
1666:Teriparatide
1585:"Cinacalcet"
1579:
1567:. Retrieved
1563:the original
1556:
1546:
1534:. Retrieved
1530:"Cinacalcet"
1495:
1474:. Retrieved
1469:
1460:
1448:. Retrieved
1443:
1434:
1409:
1405:
1399:
1377:. Retrieved
1364:
1355:
1333:. Retrieved
1320:
1311:
1289:. Retrieved
1276:
1249:. Retrieved
1241:
1197:. Retrieved
1190:
1148:. Retrieved
1139:
1113:. Retrieved
1104:
1095:
1083:. Retrieved
1078:
1037:calcimimetic
1034:
1026:Pharmacology
1009:
1006:Interactions
948:
936:
933:
912:paresthesias
908:Hypocalcemia
906:
898:
895:
860:
845:
842:Medical uses
836:
825:
805:calcimimetic
788:
784:
783:
772:
766:
370:
366:
324:Elimination
206:Legal status
200:Legal status
106:License data
29:
1736:Calcifediol
1629:homeostasis
1569:26 February
1476:8 September
1291:23 December
1251:23 December
1199:24 December
1085:24 December
924:convulsions
693: g·mol
639:100.208.116
569:CHEBI:48390
394:226256-56-0
349:Identifiers
92:MedlinePlus
64:Trade names
1817:Categories
1751:Cinacalcet
1741:Calcitriol
1715:Cinacalcet
1694:Calcitonin
1536:29 October
1379:7 December
1361:"Sensipar"
1335:7 December
1150:7 December
1115:7 December
1056:References
817:allosteric
785:Cinacalcet
698:3D model (
686:Molar mass
522:UAZ6V7728S
493:ChemSpider
453:IUPHAR/BPS
385:CAS Number
358:IUPAC name
318:-mediated)
299:Metabolism
125:Cinacalcet
34:Cinacalcet
1771:Evocalcet
1699:Elcatonin
1470:Drugs.com
1444:Drugs.com
1079:Drugs.com
337:Excretion
326:half-life
293:93 to 97%
281:20 to 25%
162:Routes of
136:Pregnancy
84:Monograph
78:Drugs.com
1807:Medicine
1426:17266540
1373:Archived
1329:Archived
1285:Archived
1192:DailyMed
1144:Archived
1109:Archived
1000:seizures
989:, feet,
957:tingling
945:Overdose
916:myalgias
869:therapy.
832:vomiting
789:Sensipar
775:(verify)
473:DrugBank
442:46506315
176:ATC code
169:By mouth
151: B3
138:category
120:DailyMed
18:Sensipar
1626:Calcium
1450:13 July
1043:of the
971:fingers
953:burning
813:tissues
809:calcium
691:357.420
656:Formula
482:DB01012
405:PubChem
304:Hepatic
192:)
186: (
184:H05BX01
122::
98:a605004
1793:Portal
1507:
1424:
1020:CYP1A2
1016:CYP3A4
1012:CYP2D6
995:throat
981:cramps
967:tongue
922:, and
920:tetany
828:nausea
724:SMILES
580:ChEMBL
549:D03505
542:D03504
502:137743
419:156419
316:CYP1A2
314:- and
312:CYP2D6
308:CYP3A4
247:℞-only
245:
232:
219:
118:
1729:Other
1501:245–6
1369:(FDA)
1365:U.S.
1325:(FDA)
1321:U.S.
1281:(FDA)
1277:U.S.
1245:(EMA)
993:, or
987:hands
973:, or
815:) by
744:InChI
700:JSmol
560:ChEBI
342:Renal
1571:2013
1538:2014
1505:ISBN
1478:2020
1452:2020
1422:PMID
1381:2019
1337:2019
1293:2019
1253:2019
1201:2019
1152:2019
1117:2019
1087:2019
1018:and
991:face
975:feet
963:lips
830:and
799:and
533:KEGG
513:UNII
462:3308
373:--3-
271:data
74:AHFS
1633:H05
1414:doi
811:on
605:EPA
432:SID
409:CID
310:-,
234:POM
189:WHO
1819::
1555:.
1519:^
1503:.
1486:^
1468:.
1442:.
1420:.
1408:.
1371:.
1363:.
1319:.
1275:.
1262:^
1240:.
1209:^
1189:.
1160:^
1138:.
1125:^
1103:.
1077:.
1064:^
969:,
965:,
914:,
858:.
834:.
795:,
670:22
664:22
369:)-
253:EU
241:US
228:UK
221:S4
215:AU
147:AU
115:US
1795::
1635:)
1631:(
1618:e
1611:t
1604:v
1587:.
1573:.
1540:.
1513:.
1480:.
1454:.
1428:.
1416::
1410:8
1394:.
1383:.
1350:.
1339:.
1306:.
1295:.
1255:.
1203:.
1154:.
1119:.
1089:.
702:)
679:N
676:3
673:F
667:H
661:C
607:)
603:(
371:N
367:R
365:(
306:(
255::
243::
230::
217::
149::
76:/
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
